Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
01 Aug, 2018, 08:00 ET
LEXINGTON, Mass., Aug. 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 at 10:00 AM ET at the InterContinental Hotel, Boston, MA.
About Aldeyra Therapeutics
Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune and metabolic diseases. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
MacDougall Biomedical Communications
SOURCE Aldeyra Therapeutics, Inc.
Share this article